Cilostazol for Prevention of Recurrent Stroke Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.

Also called NCT07174414

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 2,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07174414
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07174414. Randomized; quadruple masking; primary purpose prevention. Start 2026-10-15 (actual); primary completion 2031-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cilostazol for Prevention of Recurrent Stroke Trial
Acronym
Clarity
Condition
Stroke Recurrence
Condition
Vascular Death
Condition
Stroke (CVA) or Transient Ischemic Attack
Condition
Recurrent Stroke
Intervention (Drug)
Cilostazol 100 mg Tablets
Intervention (Drug)
Placebo
Lead sponsor
Stanford University (class: other)
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS) (class: US National Institutes of Health)
Collaborator
Yale University (class: other)
Collaborator
University of Cincinnati (class: other)
Collaborator
Medical University of South Carolina (class: other)

Record details

Record id
cardio:ct-nct07174414
Content hash
94f0d10e3d91e35b4273f134cf2ce03e8adcda58218cfd3fd2017b924d042641